SCYX
SCYNEXIS, Inc.
Price Chart
Latest Quote
$4.05
+0.25 (+6.58%)
Current Price
| Previous Close | $3.80 |
| Open | $3.84 |
| Day High | $4.06 |
| Day Low | $3.82 |
| Volume | 177,927 |
Stock Information
| Shares Outstanding | 9.93M |
| Total Debt | $2.06M |
| Cash Equivalents | $59.26M |
| Revenue | $20.34M |
| Net Income | $-24.52M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $40.22M |
| EPS (TTM) | $-3.85 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-16.98M |
| Sales | $20.34M |
| Income | $-24.52M |
| Book/sh | $0.67 |
| Cash/sh | $5.97 |
| Employees | 18 |
Financial Ratios
| Quick Ratio | 3.73 |
| Current Ratio | 3.94 |
| Debt/Eq | 4.99 |
Returns & Margins
| ROA | -20.96% |
| ROE | -53.39% |
| Gross Margin | 100.00% |
| Operating Margin | -119.95% |
| Profit Margin | -120.51% |
Ownership
| Insider Ownership | 2.10% |
| Institutional Ownership | 42.33% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.61 |
| P/S | 1.98 |
| P/B | 6.08 |
Analyst Data
| Recommendation | none |
| Target Price | $33.55 |
Technical Indicators
| SMA20 | $4.81 |
| SMA50 | $6.41 |
| SMA200 | $6.23 |
| RSI | 20.56 |
| ATR | 0.3714 |
| Shares Float | 7.70M |
| Short Float | 3.31% |
| Short Ratio | 6.26 |
| Rel Volume | 2.67 |
Performance History
| Week | -4.59% |
| Month | -22.95% |
| Quarter | -43.37% |
| 6 Months | -19.77% |
| YTD | -20.77% |
| Year | -32.50% |
| 3 Years | -82.48% |
| 5 Years | -93.77% |
| 10 Years | -98.09% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $4.05 | 209,300 |
| 2026-06-17 | $3.80 | 107,800 |
| 2026-06-16 | $4.09 | 104,700 |
| 2026-06-15 | $4.09 | 48,100 |
| 2026-06-12 | $4.23 | 51,500 |
| 2026-06-11 | $4.24 | 46,800 |
| 2026-06-10 | $4.15 | 37,400 |
| 2026-06-09 | $4.36 | 55,200 |
| 2026-06-08 | $4.45 | 50,100 |
| 2026-06-05 | $4.71 | 65,500 |
| 2026-06-04 | $4.88 | 81,500 |
| 2026-06-03 | $4.67 | 66,700 |
| 2026-06-02 | $5.10 | 62,800 |
| 2026-06-01 | $5.33 | 161,700 |
| 2026-05-29 | $5.64 | 65,588 |
| 2026-05-28 | $5.88 | 84,413 |
| 2026-05-27 | $5.61 | 96,300 |
| 2026-05-26 | $5.45 | 69,138 |
| 2026-05-22 | $5.85 | 52,850 |
| 2026-05-21 | $5.68 | 50,325 |
| 2026-05-20 | $5.34 | 58,550 |
| 2026-05-19 | $5.26 | 33,713 |
About SCYNEXIS, Inc.
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
đ° Latest News
Upcoming Stock Splits This Week (June 1 to June 5) â Stay Invested
TipRanks âĸ 2026-06-01T06:14:00Z
SCYNEXIS Enters $40 Million Private Placement, Completes Acquisition of PXL-770 to Treat Kidney Disease
MT Newswires âĸ 2026-03-31T11:59:01ZSCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy
Insider Monkey âĸ 2026-03-12T07:38:03Z
Scynexis: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-04T22:36:43ZHere's Why We're A Bit Worried About SCYNEXIS' (NASDAQ:SCYX) Cash Burn Situation
Simply Wall St. âĸ 2025-11-10T11:58:30Z
Scynexis: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-05T21:51:03ZSCYNEXIS Reports Positive Phase 1 Results for Second-Generation Antifungal SCY-247
Insider Monkey âĸ 2025-10-24T12:07:20Z
SCYNEXIS announces favourable Phase I data for SCY-247 trial
Clinical Trials Arena âĸ 2025-10-01T11:10:32Z
SCYNEXIS Second Quarter 2025 Earnings: Beats Expectations
Simply Wall St. âĸ 2025-08-15T10:13:57Z
Scynexis: Q2 Earnings Snapshot
Associated Press Finance âĸ 2025-08-13T20:35:09Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $20,601,000 | $3,746,000 | $140,141,000 | $5,091,000 |
| Operating Revenue | $20,601,000 | $3,746,000 | $140,141,000 | $5,091,000 |
| Reconciled Cost Of Revenue | - | $0 | $15,624,000 | $628,000 |
| Cost Of Revenue | - | $0 | $15,624,000 | $628,000 |
| Expenses | ||||
| Interest Expense | $173,000 | $828,000 | $3,130,000 | $5,198,000 |
| Total Expenses | $36,675,000 | $40,863,000 | $67,472,000 | $90,848,000 |
| Other Income Expense | $5,773,000 | $14,243,000 | $-3,320,000 | $23,620,000 |
| Net Non Operating Interest Income Expense | $1,692,000 | $1,737,000 | $-2,170,000 | $-5,372,000 |
| Total Other Finance Cost | $312,000 | $1,726,000 | $2,994,000 | $1,589,000 |
| Interest Expense Non Operating | $173,000 | $828,000 | $3,130,000 | $5,198,000 |
| Operating Expense | $36,675,000 | $40,863,000 | $51,848,000 | $90,220,000 |
| Other Non Operating Income Expenses | - | $235,000 | - | $3,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-8,609,000 | $-21,288,000 | $67,041,000 | $-62,809,000 |
| Net Interest Income | $1,692,000 | $1,737,000 | $-2,170,000 | $-5,372,000 |
| Interest Income | $2,177,000 | $4,291,000 | $3,954,000 | $1,415,000 |
| Normalized Income | $-14,382,000 | $-32,354,320 | $70,357,680 | $-84,781,776 |
| Net Income From Continuing And Discontinued Operation | $-8,609,000 | $-21,288,000 | $67,041,000 | $-62,809,000 |
| Total Operating Income As Reported | $-16,074,000 | $-37,117,000 | $72,669,000 | $-85,757,000 |
| Net Income Common Stockholders | $-8,609,000 | $-21,288,000 | $67,041,000 | $-62,809,000 |
| Net Income | $-8,609,000 | $-21,288,000 | $67,041,000 | $-62,809,000 |
| Net Income Including Noncontrolling Interests | $-8,609,000 | $-21,288,000 | $67,041,000 | $-62,809,000 |
| Net Income Continuous Operations | $-8,609,000 | $-21,288,000 | $67,041,000 | $-62,809,000 |
| Pretax Income | $-8,609,000 | $-21,137,000 | $67,179,000 | $-67,509,000 |
| Interest Income Non Operating | $2,177,000 | $4,291,000 | $3,954,000 | $1,415,000 |
| Operating Income | $-16,074,000 | $-37,117,000 | $72,669,000 | $-85,757,000 |
| Gross Profit | - | $3,746,000 | $124,517,000 | $4,463,000 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-1.36 | $-3.52 | $11.12 | $-11.76 |
| Basic EPS | $-1.36 | $-3.52 | $11.20 | $-11.76 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $2,941,680 | $-3,320 | $1,644,224 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-14,209,000 | $-34,317,000 | $74,209,000 | $-85,322,000 |
| Total Unusual Items | $5,773,000 | $14,008,000 | $-3,320,000 | $23,617,000 |
| Total Unusual Items Excluding Goodwill | $5,773,000 | $14,008,000 | $-3,320,000 | $23,617,000 |
| EBITDA (Bullshit earnings) | $-8,436,000 | $-20,309,000 | $70,889,000 | $-61,705,000 |
| EBIT | $-8,436,000 | $-20,309,000 | $70,309,000 | $-62,311,000 |
| Diluted Average Shares | $6,241,672 | $6,064,134 | $6,048,822 | $5,326,688 |
| Basic Average Shares | $6,241,672 | $6,064,134 | $5,981,604 | $5,326,688 |
| Diluted NI Availto Com Stockholders | $-8,609,000 | $-21,288,000 | $67,041,000 | $-62,809,000 |
| Tax Provision | $0 | $151,000 | $138,000 | $-4,700,000 |
| Gain On Sale Of Security | $5,773,000 | $14,008,000 | $-3,320,000 | $23,617,000 |
| Research And Development | $22,280,000 | $26,405,000 | $30,928,000 | $27,259,000 |
| Selling General And Administration | $14,395,000 | $14,458,000 | $20,920,000 | $62,961,000 |
| Reconciled Depreciation | - | $0 | $580,000 | $606,000 |
| Other Special Charges | - | - | - | - |
| Other Taxes | - | - | - | - |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $49,376,000 | $55,077,000 | $72,962,000 | $2,825,000 |
| Total Assets | $59,027,000 | $90,643,000 | $128,412,000 | $87,810,000 |
| Total Non Current Assets | $18,653,000 | $18,462,000 | $26,296,000 | $8,749,000 |
| Other Non Current Assets | $109,000 | $109,000 | $163,000 | $5,674,000 |
| Non Current Deferred Assets | $533,000 | $417,000 | $175,000 | $73,000 |
| Investmentin Financial Assets | $16,247,000 | $15,846,000 | $23,594,000 | $0 |
| Current Assets | $40,374,000 | $72,181,000 | $102,116,000 | $79,061,000 |
| Other Current Assets | $17,000 | $1,234,000 | $4,906,000 | $62,000 |
| Restricted Cash | $80,000 | $435,000 | $380,000 | $55,000 |
| Prepaid Assets | $246,000 | $950,000 | $642,000 | $2,441,000 |
| Receivables | $0 | $10,262,000 | $21,826,000 | $2,101,000 |
| Cash Cash Equivalents And Short Term Investments | $40,031,000 | $59,300,000 | $74,362,000 | $73,503,000 |
| Cash And Cash Equivalents | $21,259,000 | $16,051,000 | $34,050,000 | $45,814,000 |
| Other Receivables | - | $10,262,000 | $21,826,000 | - |
| Goodwill And Other Intangible Assets | - | - | $0 | $408,000 |
| Inventory | - | - | $0 | $899,000 |
| Accounts Receivable | - | - | $0 | $2,101,000 |
| Debt | ||||
| Total Debt | $2,175,000 | $16,270,000 | $15,080,000 | $48,597,000 |
| Long Term Debt And Capital Lease Obligation | $1,692,000 | $2,175,000 | $14,740,000 | $48,315,000 |
| Current Debt And Capital Lease Obligation | $483,000 | $14,095,000 | $340,000 | $282,000 |
| Current Debt | - | $13,688,000 | - | - |
| Other Current Borrowings | - | $13,688,000 | - | - |
| Long Term Debt | - | - | $12,159,000 | $45,394,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $9,651,000 | $35,566,000 | $55,450,000 | $84,577,000 |
| Total Non Current Liabilities Net Minority Interest | $3,917,000 | $11,467,000 | $39,147,000 | $66,959,000 |
| Derivative Product Liabilities | $2,225,000 | $7,998,000 | $21,680,000 | $18,644,000 |
| Non Current Deferred Liabilities | $0 | $1,294,000 | $2,727,000 | $0 |
| Current Liabilities | $5,734,000 | $24,099,000 | $16,303,000 | $17,618,000 |
| Current Deferred Liabilities | $235,000 | $1,642,000 | $1,189,000 | $0 |
| Payables And Accrued Expenses | $3,509,000 | $6,599,000 | $12,952,000 | $9,249,000 |
| Payables | $2,225,000 | $4,569,000 | $7,149,000 | $5,937,000 |
| Accounts Payable | $2,225,000 | $4,569,000 | $7,149,000 | $5,937,000 |
| Other Current Liabilities | - | - | $130,000 | $5,771,000 |
| Other Non Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $49,376,000 | $55,077,000 | $72,962,000 | $3,233,000 |
| Total Equity Gross Minority Interest | $49,376,000 | $55,077,000 | $72,962,000 | $3,233,000 |
| Stockholders Equity | $49,376,000 | $55,077,000 | $72,962,000 | $3,233,000 |
| Retained Earnings | $-385,144,000 | $-376,535,000 | $-355,247,000 | $-422,288,000 |
| Other | ||||
| Ordinary Shares Number | $5,442,688 | $4,746,748 | $4,650,974 | $4,085,292 |
| Share Issued | $5,442,688 | $4,746,748 | $4,650,974 | $4,085,292 |
| Tangible Book Value | $49,376,000 | $55,077,000 | $72,962,000 | $2,825,000 |
| Invested Capital | $49,376,000 | $68,765,000 | $85,121,000 | $48,627,000 |
| Working Capital | $34,640,000 | $48,082,000 | $85,813,000 | $61,443,000 |
| Capital Lease Obligations | $2,175,000 | $2,582,000 | $2,921,000 | $3,203,000 |
| Total Capitalization | $49,376,000 | $55,077,000 | $85,121,000 | $48,627,000 |
| Additional Paid In Capital | $434,474,000 | $431,571,000 | $428,169,000 | $425,485,000 |
| Capital Stock | $46,000 | $41,000 | $40,000 | $36,000 |
| Common Stock | $46,000 | $41,000 | $40,000 | $36,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $0 | $1,294,000 | $2,727,000 | $0 |
| Long Term Capital Lease Obligation | $1,692,000 | $2,175,000 | $2,581,000 | $2,921,000 |
| Current Deferred Revenue | $235,000 | $1,642,000 | $1,189,000 | $0 |
| Current Capital Lease Obligation | $483,000 | $407,000 | $340,000 | $282,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,507,000 | $1,763,000 | $1,692,000 | $2,316,000 |
| Current Accrued Expenses | $1,284,000 | $2,030,000 | $5,803,000 | $3,312,000 |
| Investments And Advances | $16,247,000 | $15,846,000 | $23,594,000 | $0 |
| Held To Maturity Securities | $16,247,000 | $15,846,000 | $23,594,000 | $0 |
| Net PPE | $1,764,000 | $2,090,000 | $2,364,000 | $2,594,000 |
| Gross PPE | $1,764,000 | $2,090,000 | $2,364,000 | $2,594,000 |
| Other Properties | $1,764,000 | $2,090,000 | $2,364,000 | $2,594,000 |
| Other Short Term Investments | $18,772,000 | $43,249,000 | $40,312,000 | $27,689,000 |
| Finished Goods | - | - | $0 | $24,000 |
| Work In Process | - | - | $0 | $610,000 |
| Raw Materials | - | - | $0 | $265,000 |
| Accumulated Depreciation | - | - | - | - |
| Machinery Furniture Equipment | - | - | - | - |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-5,283,000 | $-24,009,000 | $60,159,000 | $-79,892,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-5,283,000 | $-24,009,000 | $60,159,000 | $-79,883,000 |
| Cash Flow From Continuing Operating Activities | $-5,283,000 | $-24,009,000 | $60,159,000 | $-79,883,000 |
| Operating Gains Losses | $-5,773,000 | $-14,008,000 | $3,320,000 | $-23,617,000 |
| Investing Activities | ||||
| Investing Cash Flow | $24,306,000 | $6,150,000 | $-34,877,000 | $-27,389,000 |
| Cash Flow From Continuing Investing Activities | $24,306,000 | $6,150,000 | $-34,877,000 | $-27,389,000 |
| Capital Expenditure | - | - | - | $-9,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $5,000 | $0 | $18,000 | $47,248,000 |
| Financing Cash Flow | $-14,170,000 | $-139,000 | $-36,721,000 | $48,602,000 |
| Cash Flow From Continuing Financing Activities | $-14,170,000 | $-139,000 | $-36,721,000 | $48,602,000 |
| Net Other Financing Charges | $-226,000 | $-195,000 | $-135,000 | $-3,664,000 |
| Net Common Stock Issuance | $5,000 | $0 | $18,000 | $47,248,000 |
| Common Stock Issuance | $5,000 | $0 | $18,000 | $47,248,000 |
| Other | ||||
| Repayment Of Debt | $-14,000,000 | $0 | $-36,646,000 | $0 |
| Interest Paid Supplemental Data | $420,000 | $840,000 | $3,248,000 | $5,190,000 |
| End Cash Position | $21,448,000 | $16,595,000 | $34,593,000 | $46,032,000 |
| Beginning Cash Position | $16,595,000 | $34,593,000 | $46,032,000 | $104,702,000 |
| Changes In Cash | $4,853,000 | $-17,998,000 | $-11,439,000 | $-58,670,000 |
| Proceeds From Stock Option Exercised | $51,000 | $56,000 | $42,000 | $18,000 |
| Net Issuance Payments Of Debt | $-14,000,000 | $0 | $-36,646,000 | $5,000,000 |
| Net Long Term Debt Issuance | $-14,000,000 | $0 | $-36,646,000 | $5,000,000 |
| Long Term Debt Payments | $-14,000,000 | $0 | $-36,646,000 | $0 |
| Net Investment Purchase And Sale | $24,306,000 | $6,150,000 | $-34,877,000 | $-27,380,000 |
| Sale Of Investment | $43,209,000 | $42,567,000 | $50,603,000 | $0 |
| Purchase Of Investment | $-18,903,000 | $-36,417,000 | $-85,480,000 | $-27,380,000 |
| Change In Working Capital | $6,083,000 | $7,283,000 | $-30,644,000 | $764,000 |
| Change In Other Working Capital | $-2,702,000 | $-979,000 | $3,916,000 | - |
| Change In Other Current Liabilities | $-407,000 | $-339,000 | $-6,053,000 | $2,355,000 |
| Change In Payables And Accrued Expense | $-3,236,000 | $-6,351,000 | $3,038,000 | $-1,551,000 |
| Change In Accrued Expense | $-1,002,000 | $-3,701,000 | $1,866,000 | $-70,000 |
| Change In Payable | $-2,234,000 | $-2,650,000 | $1,172,000 | $-1,481,000 |
| Change In Account Payable | $-2,234,000 | $-2,650,000 | $1,172,000 | $-1,481,000 |
| Change In Prepaid Assets | $2,166,000 | $3,388,000 | $-2,971,000 | $1,636,000 |
| Change In Receivables | $10,262,000 | $11,564,000 | $-19,725,000 | $-1,240,000 |
| Other Non Cash Items | $638,000 | $1,998,000 | $3,224,000 | $1,796,000 |
| Stock Based Compensation | $2,852,000 | $3,346,000 | $2,624,000 | $3,686,000 |
| Amortization Of Securities | $-474,000 | $-1,340,000 | $-1,340,000 | $-309,000 |
| Gain Loss On Investment Securities | $-5,773,000 | $-14,008,000 | $3,320,000 | $-23,617,000 |
| Net Income From Continuing Operations | $-8,609,000 | $-21,288,000 | $67,041,000 | $-62,809,000 |
| Change In Inventory | - | $0 | $-8,849,000 | $-436,000 |
| Changes In Account Receivables | - | $0 | $2,101,000 | $-1,240,000 |
| Asset Impairment Charge | - | $0 | $15,354,000 | $0 |
| Depreciation Amortization Depletion | - | $0 | $580,000 | $606,000 |
| Depreciation And Amortization | - | $0 | $580,000 | $606,000 |
| Issuance Of Debt | - | - | $0 | $5,000,000 |
| Long Term Debt Issuance | - | - | $0 | $5,000,000 |
| Net Intangibles Purchase And Sale | - | - | $0 | $-9,000 |
| Purchase Of Intangibles | - | - | $0 | $-9,000 |
| Net PPE Purchase And Sale | - | - | - | - |
| Purchase Of PPE | - | - | - | - |
Fetched: 2026-06-19